Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Bolt Biotherapeutics Inc
(NQ:
BOLT
)
0.7306
+0.0006 (+0.08%)
Streaming Delayed Price
Updated: 1:21 PM EDT, Jul 25, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Bolt Biotherapeutics Inc
< Previous
1
2
Next >
BOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
July 24, 2024
From
Schall Law
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against NIKE, FutureFuel, SeaStar, and Bolt and Encourages Investors to Contact the Firm
July 22, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
BOLT Stockholders Should Contact Shareholder Rights Law Firm Robbins LLP for Information About the Class Action Against Bolt Biotherapeutics, Inc.
July 22, 2024
From
Robbins LLP
Via
GlobeNewswire
BOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
July 22, 2024
From
The Schall Law Firm
Via
Business Wire
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt
July 18, 2024
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against FutureFuel, SeaStar, and Bolt and Encourages Investors to Contact the Firm
July 17, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
BOLT Stockholders with Large Losses Should Contact Robbins LLP for Information About the Bolt Biotherapeutics, Inc. Class Action Lawsuit
July 15, 2024
From
Robbins LLP
Via
Business Wire
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Bolt Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BOLT
July 15, 2024
From
The Rosen Law Firm PA
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against SeaStar and Bolt and Encourages Investors to Contact the Firm
July 13, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
BOLT Class Action Alert: Robbins LLP Reminds Stockholders of the Lead Plaintiff Deadline in the Class Action Against Bolt Biotherapeutics, Inc.
July 10, 2024
From
Robbins LLP
Via
GlobeNewswire
BOLT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Bolt Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
July 10, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
BOLT ALERT: Bragar Eagel & Squire, P.C. is Investigating Bolt Biotherapeutics, Inc. on Behalf of Bolt Stockholders and Encourages Investors to Contact the Firm
July 09, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Bolt Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BOLT
July 08, 2024
From
The Rosen Law Firm PA
Via
GlobeNewswire
Bolt Biotherapeutics, Inc. Stockholder Notice: Robbins LLP Reminds Investors of the BOLT Class Action
July 08, 2024
From
Robbins LLP
Via
Business Wire
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Bolt Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BOLT
July 05, 2024
From
The Rosen Law Firm PA
Via
GlobeNewswire
Shareholder Alert: Robbins LLP Informs Stockholders of the Class Action Filed Against Bolt Biotherapeutics, Inc. (BOLT)
July 03, 2024
From
Robbins LLP
Via
GlobeNewswire
BOLT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Bolt Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
July 03, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
ROSEN, A TOP RANKED LAW FIRM, Encourages Bolt Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BOLT
July 03, 2024
From
The Rosen Law Firm, P.A.
Via
Business Wire
Bolt Biotherapeutics Reports First Quarter 2024 Results, Announces Strategic Pipeline Prioritization and Changes to Leadership Team
May 14, 2024
From
Bolt Biotherapeutics, Inc.
Via
GlobeNewswire
Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
March 21, 2024
From
Bolt Biotherapeutics, Inc.
Via
GlobeNewswire
Bolt Biotherapeutics to Present at the TD Cowen 44th Annual Healthcare Conference
February 27, 2024
From
Bolt Biotherapeutics, Inc.
Via
GlobeNewswire
Pacira Appoints Frank D. Lee as Chief Executive Officer
December 21, 2023
From
Pacira BioSciences
Via
GlobeNewswire
Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu®
December 05, 2023
From
Bolt Biotherapeutics, Inc.
Via
GlobeNewswire
Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
November 09, 2023
From
Bolt Biotherapeutics, Inc.
Via
GlobeNewswire
Bolt Biotherapeutics to Present at Stifel 2023 Healthcare Conference
November 07, 2023
From
Bolt Biotherapeutics, Inc.
Via
GlobeNewswire
10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis
October 23, 2023
Via
ACCESSWIRE
Bolt Biotherapeutics Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 Congress
October 23, 2023
From
Bolt Biotherapeutics, Inc.
Via
GlobeNewswire
Bolt Biotherapeutics to Present Data at the Society for Immunotherapy of Cancer’s 2023 Annual Meeting
October 18, 2023
From
Bolt Biotherapeutics, Inc.
Via
GlobeNewswire
Bolt Biotherapeutics Announces First Patient Dosed in Phase 1/2 Study of BDC-3042 in Patients with Advanced Cancers
October 17, 2023
From
Bolt Biotherapeutics, Inc.
Via
GlobeNewswire
Bolt Biotherapeutics to Present New Clinical Data from Completed Phase 1/2 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Solid Tumors at the ESMO Congress 2023
October 16, 2023
From
Bolt Biotherapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.